|Table of Contents|

Expression levels of serum VEGF-A and EFNA1 in patients with papillary thyroid carcinoma and their correlation with cervical lymph node metastasis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 02
Page:
218-225
Research Field:
Publishing date:

Info

Title:
Expression levels of serum VEGF-A and EFNA1 in patients with papillary thyroid carcinoma and their correlation with cervical lymph node metastasis
Author(s):
WANG Chun1; ZHANG Linlin2; ZHAO Hongjian2; XING Hao3; YIN Fengyan3; ZHANG Hui3; CAO Wenyuan1; LUO Xiaoting1; HE Qian1; XING Weijia1
1.School of Public Health and Health Management,Shandong First Medical University,Shandong Ji'nan 250000,China;2.Department of Hepatobiliary Surgery,Chengwu People's Hospital,Shandong Heze 274000,China;3.Department of Thyroid Surgery,Taian City Central Hospital,Shandong Tai'an 271000,China.
Keywords:
papillary thyroid carcinoma; lymph node metastasis; vascular endothelial growth factor A; ephrin-A1
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2025.02.008
Abstract:
Objective:To investigate the relationship between the expression levels of serum vascular endothelial growth factor A(VEGF-A) and ephrin-A1(EFNA1) and cervical lymph node metastasis(LNM) in patients with papillary thyroid carcinoma(PTC).Methods：The 276 serum samples of PTC patients who underwent thyroidectomy and confirmed by pathology after thyroidectomy were included.The expression levels of VEGF-A and EFNA1 in serum were determined by enzyme-linked immuno sorbent assay(ELISA).The clinical and pathological data of the patients were collected,and the relationship between the expression of VEGF-A and EFNA1 and PTC LNM was analyzed by Logistic regression,and the best cut-off value was determined by ROC curve.Results：The expression level of VEGF-A in PTC LNM group was higher than that in PTC without LNM group（P＜0.05）,while the expression level of EFNA1 in PTC LNM group was lower than that in PTC without LNM group（P＜0.05）.Logistic regression analysis showed that VEGF-A may be an independent risk factor for PTC LNM,while EFNA1 may be a protective factor for PTC LNM.There was significant difference between VEGF-A expression level and serum iodine level,and there was significant difference between EFNA1 expression level and tumor location and Hashimoto's thyroiditis. Conclusion：The expressions of VEGF-A have a certain predictive value for the diagnosis of PTC LNM.

References:

［1］SHIN YS,JOO MK,JIN HS,et al.Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells,contributing to angiogenesis and tumor growth［J］.Clinical Cancer Research,2019,25(1):414-425.
［2］JINA K,JESSICA GE,ROMAN SA.Geographic influences in the global rise of thyroid cancer［J］.Nature Reviews,Endocrinology,2020,16(1):17-29.
［3］DU R,ZHANG Y,KOU J,et al.A novel risk stratification model based on tumor size and multifocality to predict recurrence in pediatric PTC:Comparison with adult PTC［J］.Frontiers in Endocrinology,2024,1(4):1298036.
［4］YUN TS,GUO HX,TIAN XW,et al.Lateral neck multilevel fine-needle aspiration cytology and thyroglobulin estimation in papillary thyroid carcinoma［J］.Laryngoscope Investigative Otolaryngology,2021,6(3):570-575.
［5］HIMANSHI D,NADEEM T,SUSHMA K.Cytological clues to the diagnosis of solid variant of papillary thyroid carcinoma［J］.Journal of Cytology,2020,37(4):214-215.
［6］VELA-GAXHA Z,SHAHINI L,MANXHUKA-KERLIU S.The prognostic role of vascular endothelial growth factor-A expression in thyroid carcinomas［J］.Folia Med(Plovdiv),2019,61(1):61-68.
［7］巩雷，陈萍，刘宪军，等.甲状腺乳头状癌中D2-40、EGFR和VEGF的表达及BRAF基因突变［J］.实用肿瘤杂志，2017，32(3):234-239. GONG L,CHEN P,LIU XJ,et al.Expression of D2-40,EGFR and VEGF and BRAF gene mutation in papillary thyroid carcinoma［J］.Journal of Practical Oncology,2017,32(3):234-239.
［8］LING YC,BIN LH,XU CH,et al.EFNA1 in gastrointestinal cancer:Expression,regulation and clinical significance［J］.World Journal of Gastrointestinal Oncology,2022,14(5):973-988.
［9］HOU XJ,SHAO XW,YING L,et al.Targeting EFNA1 suppresses tumor progression via the cMYC-modulated cell cycle and autophagy in esophageal squamous cell carcinoma［J］.Discover Oncology,2023,14(1):64.
［10］刘新悦，赵鸿渐，邢浩，等.不同碘水平下血清外泌体miRNA的表达对甲状腺乳头状癌淋巴结转移的早期诊断价值［J］.现代肿瘤医学，2023，31(16):3014-3018. LIU XY,ZHAO HJ,XING H,et al.The early diagnostic value of serum exosome miRNA expression under different iodine levels for lymph node metastasis in papillary thyroid carcinoma ［J］.Modern Oncology,2023,31 (16):3014-3018.
［11］BYTNAR AJ,ENEWOLD L,SHRIVER DC,et al.Incidence of papillary thyroid cancer:Comparison of the military and the general population by race and tumor stage/size［J］.Cancer Epidemiology,2024,8(9):102539.
［12］SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA:A Cancer Journal for Clinicians,2023,73(1):17-48.
［13］HAUGEN BR,ALEXANDER EK,BIBLE KC,et al.2015 american thyroid association management guidelines for adult patients with thyroid nodulesand differentiated thyroid cancer:The american thyroid association guidelines task forceon thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):1-133.
［14］李楠楠.甲状腺球蛋白联合血清CEA鉴别甲状腺良、恶性肿瘤中的应用价值［J］.微量元素与健康研究，2022，39(6):16-17. LI NN.Application value of thyroglobulin combined with serum CEA in the identification of benign and malignant thyroid tumors［J］.Trace Elements and Health Research,2022,39(6):16-17.
［15］宋建明，邹良英，曾琪，等.常规超声结合弹性分级与应变比在甲状腺癌转移性淋巴结中的应用［J］.中国超声医学杂志，2024，40(1):8-12. SONG JM,ZOU LY,ZENG Q,et al.Application of conventional ultrasound combined with elastic grading and strain ratio in metastatic lymph nodes of thyroid cancer［J］.Chinese Journal of Ultrasound Medicine,2024,40(1):8-12.
［16］MEILING Z,LIU ZZ,KEISUKE A,et al.CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression［J］.Science Translational Medicine,2022,14(630):eabf5473.
［17］BOSSI P,VIALE G,LEE AK,et al.Angiogenesis in colorectal tumors:Microvessel quantitation in adenomas and carcinomas with clinicopathological correlations［J］.Cancer Res,1995,55(21):5049-5053.
［18］LIU D,WANG N,SUN Y,et al.Expression of VEGF with tumor incidence,metastasis and prognosis in human gastric carcinoma［J］.Cancer Biomarkers,2018,22(4):693-700.
［19］HU CJ,WU ZF,HUANG ZH,et al.Nox2 impairs VEGF-A-induced angiogenesis in placenta via mitochondrial ROS-STAT3 pathway［J］.Redox Biol,2021,4(5):102051.
［20］RAJENDRA SA,DANIEL SC,NAPOLEONE F.VEGF in signaling and disease:Beyond discovery and development［J］.Cell,2019,176(6):1248-1264.
［21］GRAUPERA M,GUILLERMET-GUIBERT J,FOUKAS LC,et al.Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration［J］.Nature,2008,453(7195):662-666.
［22］LIM W,BAE H,BAZER FW,et al.Ephrin A1 promotes proliferation of bovine endometrial cells with abundant expression of proliferating cell nuclear antigen and cyclin D1 changing the cell population at each stage of the cell cycle［J］.Cell Physiol,2019,234(4):4864-4873.
［23］CHENG N,CHEN J.Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism［J］.Biol Chem,2001,276(17):13771-13777.
［24］MANTOVANI G,MARIA SF,FREDIANO I,et al.Molecular pathways in vulvar squamous cell carcinoma:Implications for target therapeutic strategies［J］.Journal of Cancer Research and Clinical Oncology,2020,146(7):1647-1658.
［25］GENEVIVE S,ZAKIA H,ANGELO F,et al.Oncogenic alterations in papillary thyroid cancers of young patients［J］.Thyroid,2012,22(1):17-26.
［26］李京佳，林相国，许涛，等.VEGF家族及其在肿瘤生长中作用的研究［J］.现代生物医学进展，2012，12(4):777-779,701. LI JJ,LIN XG,XU T,et al.Study on VEGF family and its role in tumor growth［J］.Advances in Modern Biomedicine,2012,12(4):777-779,701.
［27］张明，汪静，周详，等.甲状腺乳头状癌患者血清中血管内皮生长因子的表达水平及其临床意义［J］.现代肿瘤医学，2021，29(15):2612-2615. ZHANG M,WANG J,ZHOU X,et al.Expression level of vascular endothelial growth factor in serum of patients with papillary thyroid carcinoma and its clinical significance［J］.Modern Oncology,2021,29(15):2612-2615.
［28］郭丽霞，兰竞丽，胡兆鹏，等．血管内皮生长因子、S100A4 及生存素在甲状腺癌组织中的表达及其意义［J］．中国基层医药，2016，23(10):1479-1482． GUO LX,LAN JL,HU ZP,et al.Expression of vascular endothelial growth factor,S100A4 and survivin in thyroid cancer tissues and their significance［J］.Chinese Primary Medicine,2016,23(10):1479-1482．
［29］蒋伟光，蒋国新.cN0期甲状腺乳头状癌中HIF-1α、VEGF表达和BRAF基因突变在中央区淋巴结转移中的意义［J］.齐齐哈尔医学院学报，2018，39(1):1-3. JIANG WG,JIANG GX.Significance of HIF-1α,VEGF expression and BRAF gene mutations in central lymph node metastasis in cN0 stage papillary thyroidcarcinoma［J］.Journal of Qiqihar Medical College,2018,39(1):1-3.
［30］HALL FT,FREEMAN JL,ASA SL,et al.Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma［J］.Archives of Otolaryngology-Head Neck Surgery,2003,129(7):716-719.
［31］HIMANEN JP,YEHUDA G,HUI M,et al.Ligand recognition by A-class Eph receptors:Crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex［J］.EMBO Reports,2009,10(7):722-728.
［32］HAO YP,WANG WY,QIAO Q,et al.EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma［J］.Medicine(Baltimore),2021,100(22):e26188.
［33］ELHAM S,AMIR K,ALI M,et al.Role of EFNA1 SNP (rs12904) in tumorigenesis and metastasis of colorectal cancer:A bioinformatic analysis andHRM SNP genotyping verification［J］.Asian Pacific Journal of Cancer Prevention,2022,23(10):3523-3531.
［34］BHAGYALAXMI S,MOHAMMED KA,FREDERIC K,et al.Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene［J］.BMC Cancer,2012,12(1):309.
［35］KHODAYARI N,MOHAMMED KA,GOLDBERG EP,et al.EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene［J］.Cancer Gene Therapy,2011,18(11):806-816.

Memo

Memo:
山东省自然科学基金（编号：ZR2023QH135）；山东省泰安市科技创新课题（编号：2022NS234)
Last Update: 1900-01-01